ENZYMATIC SYNTHESIS AND CHROMATOGRAPHIC PURIFICATION OF L-3-[<sup>11</sup>C]-LACTIC ACID VIA D,L-3-[<sup>11</sup>C]-ALANINE

G. Kloster and P. Laufer

Institut für Chemie 1 (Nuklearchemie) der Kernforschungsanlage Jülich GmbH, D-5170 Jülich, FRG

### SUMMARY

D,L-3-[<sup>11</sup>C]-Alanine was prepared by methylation with <sup>11</sup>CH<sub>3</sub>I of tert.butyl 2-isocyanoacetate and subsequent hydrolysis. Enzymatic reaction using glutamate pyruvate transaminase and lactate dehydrogenase in a coupled reaction yields L-3-[<sup>11</sup>C]-lactic acid. The radiochemical yield is 45% for D,L-alanine and 26.5% for L-lactic acid at a specific activity of 0.45 mCi/µmole. Synthesis time including purification by hplc is 23 min for D,L-3-[<sup>11</sup>C]-alanine and 45 min for L-3-[<sup>11</sup>C]-lactic acid, respectively.

Key words: Carbon-11, Alanine, Lactic Acid, Enzymatic synthesis

# INTRODUCTION

L-lactic acid is a normal intermediate of carbohydrate and amino acid metabolism. During oxidative metabolism, it is oxidized to CO<sub>2</sub> and H<sub>2</sub>O, whereas during oxygen deprivation, it is generated from glycolysis and accumulates in tissues and blood. Normal myocardium is known to take up free fatty acids to generate 2/3 of its energy needs; the other 1/3 is generated from carbohydrate derivatives, including L-lactate. In addition to our investigations of labelled fatty acids (1,2), in particular 0362-4803/80/0617-0889\$01.00 ©1980 by John Wiley & Sons, Ltd. Revised August 1, 1979  $\omega^{-123}$ I-heptadecanoic acid, as tools for probing regional myocardial metabolism (3), we decided to synthesize L-lactic acid, which should enable us to probe regional myocardial metabolism using the path of carbohydrate derivatives. D,L-<sup>11</sup>C-lactic acid was one of the first <sup>11</sup>C-labelled compounds, and was synthesized by Cramer and Kistiakowsky in 1941 (4). Later, D,L-1-<sup>11</sup>C-lactic acid was prepared via H<sup>11</sup>CN by Winstead et al. (5). L-1-<sup>11</sup>C-lactic acid was enzymatically prepared from <sup>11</sup>CO<sub>2</sub> by Cohen et al. (6). Those syntheses, however, have some drawbacks: in two of them (4,5) D,L-lactic acid is obtained as product, which means that 50% of the activity to be injected is in the D-form which cannot be utilized by man. The third one (6), though producing pure L-lactic acid, was reported to have a rather low radiochemical yield of only 3 to 5%. We therefore decided to follow a different route, introducing the label into the 3-position via <sup>11</sup>CH<sub>2</sub>I (Scheme 1).

$$\underset{\text{Li-CH-CO}_2-C_4H_9}{\text{NC}} \xrightarrow{1. \ 11CH_3I}_{2. \ H^{\textcircled{0}}} \xrightarrow{11CH_3 - CH - CO_2H}_{NH_2} \xrightarrow{\text{GPT}}_{NH_2}$$

$$^{11}CH_3 - \overset{H}{\overset{}_{C}} - CO_2H$$

SCHEME 1

### EXPERIMENTAL

Tertiary butyl 2-isocyanoacetate and its anion was prepared according to Schöllkopf et al. (7).

Practically carrier-free  ${}^{11}CH_3I$  was prepared according to Marazano et al. (8).

- A typical preparation of  $L-3-^{11}C$ -lactate runs as follows: After transferring practically carrier-free <sup>11</sup>CH<sub>2</sub>I  $t = 0 \min$ (22.4 mCi) into a solution of 50 mg of the lithium salt of tert.butyl 2-isocyanoacetate in 500 µl THF at -78 <sup>O</sup>C, the mixture is stirred for 3 min at -78 <sup>O</sup>C and another 3 min at room temperature. 2 ml of 5 N HCl are added to the solution, which is  $t \approx 6 \min$ decolourized immediately. The resulting mixture is heated at 80 °C for 2 min. The solution is evaporated to complete dryness using a rotary evaporator. The residue is dissolved in 1 ml of 50 mM phosphate  $t = 15 \min$ buffer pH 7.5 and heated at 37 <sup>O</sup>C. 5 mg of NADH, 5 mg of  $\alpha$ -ketoglutarate and 550 U of lactate dehydrogenase are added to this solution. The enzymatic reaction is started by addition of 8 U of glutamate pyruvate transaminase. After a 6 min reaction time, the reaction is stopped by heating the mixture at 100 <sup>O</sup>C for 30 sec. The denatured enzymes are separated by centrifugation.
- t = 28 min The clear supernatant is evaporated to dryness;  $^{11}C$ -lactic acid is extracted from the residue with 2x1 ml ethanol. This treatment dissolves almost all  $^{11}C$ -lactic acid, while leaving most of the NADH and  $\alpha$ -ketoglutarate undissolved.
- t = 37 min The solution is injected onto a hplc-column (Li-ChroSorb KAT/H<sup>+</sup> 10  $\mu$  25x1 cm) via a sample valve. At a flow rate of 9.9 ml/min using ethanol as eluent, L-3-<sup>11</sup>C-lactic acid elutes with a retention time of 2 min. The L-3-<sup>11</sup>C-lactic acid peak is collected and evaporated to dryness.

A radiochemical yield of 5.9 mCi  $\triangleq$  26.5% (decay corrected) was obtained with a specific activity of about 0.45 mCi/µmole.

This reaction sequence can be used to prepare D,L-3-<sup>11</sup>Calanine as well. In this case, the residue left over after the t = 15 min step is dissolved in 1 ml of ethanol. The solution is injected onto a hplc-column (Latek SiO<sub>2</sub> 10  $\mu$  21.5x1 cm) via a sample valve. At a flow rate of 5 ml/min, a mixture of 4 parts of ethanol with 1 part of 0.4% aqueous Na<sub>2</sub>HPO<sub>4</sub>-solution is used as eluent. Under these conditions D,L-3-<sup>11</sup>C-alanine is eluted with a retention time of 4 min. In a typical preparation, 4.0 mCi of D,L-3-<sup>11</sup>C-alanine are obtained from 8.8 mCi of <sup>11</sup>CH<sub>3</sub>I in 23 min; the radiochemical yield is 45% at the same specific activity as stated above for L-3-<sup>11</sup>C-lactic acid.

Addition of carrier methyl iodide to the reaction mixture does not change the radiochemical yield. During preparation of <sup>11</sup>CH<sub>3</sub>I, about 2 µmole of nonradioactive CH<sub>3</sub>I are also generated, probably from atmospheric CO<sub>2</sub>; therefore, alanine and lactic acid are not carrier-free.

The hplc conditions (see Table 1) were selected to yield a salt-free residue of L-3-<sup>11</sup>C-lactic acid. In order to characterize the L-3-<sup>11</sup>C-lactic acid unequivocally, we chromatographed the <sup>11</sup>C-compound eluted from the preparative column at k' = 0.7 on a second column (LiChroSorb RP18 10  $\mu$ , 25x1 cm). In both cases, the radio-activity is eluted at the same position as authentic L-lactic acid.

column/eluent	k' alanine	k' lactate
Latek SiO <sub>2</sub> 10 µ/O.4% Na <sub>2</sub> HPO <sub>4</sub> : EtOH 4:1 (5 ml/min)	1.35	-
LiChroSorb RP18 10 µ O.O1 N HCl (5 ml/min)	1.2	1.8
LiChroSorb KAT/H <sup>Φ</sup> 10 μ EtOH (9.9 ml/min)	ω	0.7

Table 1. HPLC-Data

 $k' = (v - v_0) / v_0$ 

## CONCLUSION

We report here a synthesis of L-3-[ $^{11}$ C]-lactic acid that proceeds with 26.5% radiochemical yield in 45 min. Compared to the synthesis of Winstead et al. (5) it has the advantage of producing only the natural L-stereoisomer instead of the racemate in shorter time and comparable yield. In comparison to the synthesis of Cohen et al. (6), who produced L-1-[ $^{11}$ C]-lactic acid from  $^{11}$ CO<sub>2</sub>, it has the advantage of using only commercially available enzymes and achieving a higher yield.

The yield of L-3-[<sup>11</sup>C]-lactic acid in our synthesis may still be enhanced if one succeeds in producing partially resolved alanine, which contains an excess of L-alanine, the precursor of L-lactic acid. This synthesis has been reported by Langström and Stridsberg (9) during the final stages of our work. They obtained a 2.9 fold excess of L-3-[<sup>11</sup>C]-alanine over D-3-[<sup>11</sup>C]-alanine using asymmetric induction. Using their synthesis of enriched L-alanine and our procedure to synthesize L-lactic acid should yield L-3-[<sup>11</sup>C]-lactic acid in radiochemical yields up to 40%.

Studies on the pharmacokinetics of L-3- $[^{11}C]$ -alanine in rabbits are being performed presently. It remains to be seen whether it is possible to measure regional myocardial metabolism in rabbits and, finally, in man using L-3- $[^{11}C]$ -lactic acid as a tracer.

#### ACKNOWLEDGEMENT

We thank Prof. Stöcklin for his constant support and stimulating discussions.

# REFERENCES

- Machulla H.-J., Stöcklin G., Kupfernagel C., Freundlieb C., Höck A., Vyska K., and Feinendegen L.E. - J.nucl.Med. <u>19</u>: 298 (1978)
- Knust E.J., Kupfernagel C., and Stöcklin G. J.nucl.Med., in press
- 3. Freundlieb C., Höck A., Vyska K., Feinendegen L.E., Machulla H.-J., and Stöcklin, G. - Radioaktive Isotope in Klinik und Forschung <u>13</u>: 265 (1978)
- 4. Cramer R.D. and Kistiakowsky G.B. J.biol.Chem. 137: 549 (1941)
- 5. Winstead M.B., Chern C.I., Lin T.H., Khentigan A., Lamb J.F., and Winchell H.S. - Int.J.appl.Radiat.Isotopes 29: 69 (1978)
- 6. Cohen M.B., Spolter L., Chang C.C., and MacDonald N.S. J.Lab.Comp.Radiopharm. 16: 63 (1979)
- 7. Schöllkopf U., Gerhart F., Schröder R., and Hoppe D. Liebigs Ann.Chem. <u>766</u>: 116 (1972)
- Marazano C., Maziere M., Berger G., and Comar D. Int.J.appl. Radiat.Isotopes 28: 49 (1977)
- 9. Långström B. and Stridsberg B. Int.J.appl.Radiat.Isotopes <u>30</u>: 151 (1979)